White Paper
Treatment Selection in Autoimmune: How Digital Can Unlock Opportunities for Biopharma
Research insights into the biggest digital health opportunities for biopharma in biologics for autoimmune conditions.
Read Now
Digital innovation is accelerating at a rapid pace in immunology.
There are huge opportunities for forward-looking biopharma companies to develop digital tools that augment their drug portfolios. Those who do so successfully will equip providers to better diagnose, treat and manage immunology patients, help patients enjoy a better quality of life and encourage payer adoption.
FOR PROVIDERS
For the most common autoimmune conditions, there are a myriad of treatments–both branded and biosimilars. Because biologics are indicated for multiple conditions, matching each patient to the right treatment can be difficult.
FOR BIOPHARMA
Without solid real-world evidence, biopharma companies face an uphill battle in telling payers a compelling value story to obtain reimbursement.
FOR PATIENTS
Successful treatment of immune conditions relies heavily on patient self-reporting. Traditional, paper-based methods of self-reporting are cumbersome, overly simplistic and only capture a moment in time.
These pain points not only inevitably result in more time wasted searching for, analyzing and/or converting data, but they also result in clinicians spending less time in patient care—and feeling more frustrated.
- Kristin Zyga, BrightInsight Senior Director of Market Research
With real-time treatment data, trial details and drug trends in one consolidated clinician dashboard, providers have the insights they need to make better treatment decisions for their patients, both today and as each patient’s condition evolves over time.
Our platform and pre-built applications allow for the creation and configuration of secure, compliant patient apps. Patients can go from point-in-time symptom tracking to comprehensive quality of life data capture, enabling better care and increasing adherence.
The BrightInsight Platform® captures real-time data from patients, providers and clinical trial participants, so biopharma companies have the insights to make a compelling case for reimbursement and identify opportunities for R&D.
Research insights into the biggest digital health opportunities for biopharma in biologics for autoimmune conditions.
Read Now
Contact us to set up a demo today.
